The National Institutes of Health selected Tulane National Primate Research Center to lead a new partnership between the seven federally funded National Primate Research Centers to combine their efforts to accelerate promising COVID-19 vaccine and drug research. The NIH contract, awarded at $1.7 million for the first year, has the potential to reach up to $6.5 million over a four-year funding period. The centers, which normally conduct research independently, will jointly coordinate their studies to provide more useful data. Jay Rappaport, principal Investigator and director of the Tulane National Primate Research Center says it will help them be more efficient in responding to emerging infectious diseases now and in the future. Vaccines and therapeutics are normally evaluated in both human and nonhuman primate populations using a less coordinated approach that makes it difficult to compare one treatment with another.